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Paraplegia is a catastrophic complication of thoracicaortic surgery. Various methods of spinal cord pro-
tection such as temporary shunts, partial bypass, and
hypothermia have been suggested to prevent this com-
plication. However, no reliable method has been devel-
oped that totally prevents the development of paraple-
gia.1 The incidence of paraplegia ranges from 2.9% to
23%2 in operations on the thoracic aorta. The mecha-
nism of spinal cord injury has been thought to involve
tissue ischemia, and the spinal motor neuron cells are
vulnerable to ischemia. However, the exact mechanism
is not fully understood.
Glial cell line–derived neurotrophic factor (GDNF)
has been recently isolated as a peptide protein of sur-
Objective: Glial cell line–derived neurotrophic factor (GDNF) has protective
effects on various injuries involving the central and peripheral nervous sys-
tems in vitro and vivo. However, the possible protective effect of GDNF on
spinal cord ischemia and the exact mechanism involved in the ameliorative
effect of GDNF on ischemic spinal cord injuries are not fully understood.
Therefore, we investigated the possible protective effect of the adenovirus-
mediated GDNF gene delivery on transient spinal cord ischemia in rabbits.
Methods: The adenoviral vector (lacZ gene as a control or GDNF gene con-
tained) was injected directly into the lumbar spinal cord via a needle insert-
ed into the dorsal spine 2 days before the animal was subjected to 15 min-
utes of spinal cord ischemia induced by infrarenal aortic occlusion. In situ
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick-
end labeling (TUNEL staining) was performed, and temporal profiles of the
GDNF and caspase-3 (caspase-3 is the marker of apoptotic change)
immunoreactivity were investigated.
Results: In the control rabbit, the majority of motor neurons showed selective
cell death at 7 days of reperfusion. Immunocytochemistry showed that in situ
TUNEL staining was selectively detected at 2 days of reperfusion in motor
neuron nuclei. GDNF and caspase-3 were selectively induced in the motor
neuron cells at 8 hours of reperfusion. In the GDNF-treated group, a large
population of motor neuron cells was still surviving at 7 days after having
been subjected to 15 minutes of ischemia. Unlike the control group, the
GDNF-treated group expressed GDNF persistently. Induction of TUNEL
staining and immunoreactivity for caspase-3 were greatly reduced by the
GDNF treatment. 
Conclusion: These results suggest that the reduction in motor neuron death
by GDNF was greatly associated with a reduction in DNA fragmentation and
apoptotic signals of the caspase-3 cascade; they further suggest a great
potential for gene therapy for paraplegic patients in the future.  (J Thorac
Cardiovasc Surg 2000;120:1148-57) 
Masahiro Sakurai, MDa,d
Koji Abe, MDb
Takeshi Hayashi, MDb
Yasuhiro Setoguchi, MDc
Gen-ya Yaginuma, MDd
Taiichiro Meguro MDd
Koichi Tabayashi, MDa
ADENOVIRUS-MEDIATED GLIAL CELL LINE–DERIVED NEUROTROPHIC FACTOR GENE DELIVERY
REDUCES MOTOR NEURON INJURY AFTER TRANSIENT SPINAL CORD ISCHEMIA IN RABBITS
From the Department of Cardiovascular Surgery, Graduate School of
Medicine, Tohoku University,a Sendai; the Department of
Neurology, Okayama University School of Medicine,b Okayama;
the Department of Respiratory Medicine, Juntendo University
School of Medicine,c Tokyo; and the Division of Heart Institute,
Sendai Kosei Hospital,d Sendai, Japan.
Received for publication Jan 7, 2000; revisions requested March 17,
2000; revisions received April 13, 2000; accepted for publication
Aug 29, 2000.
Address for reprints: Masahiro Sakurai, MD, Department of
Cardiovascular Surgery, Graduate School of Medicine, Tohoku
University, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
Copyright © 2000 by The American Association for Thoracic
Surgery
0022-5223/2000 $12.00 + 0 12/1/111178
doi:10.1067/mtc.2000.111178
vival and neurite outgrowth of dopaminergic and motor
neurons, as well as peripheral sensory and sympathetic
neurons,3,4 and is structurally related to members of the
transforming growth factor β superfamily.5 It has been
reported that GDNF has protective effects on various
injuries to the central and peripheral nervous systems
in vitro and vivo.4,6,7 We8 have demonstrated that topi-
cal application of GDNF significantly ameliorates
brain edema formation in the ischemic rat brain in
association with a reduction in TUNEL staining (ter-
minal deoxynucleotidyl transferase [TdT]-mediated
dUTP-biotin nick-end labeling). However, such pro-
teins are greatly limited for use in ischemic neurons as
pharmaceutical agents because it is difficult for them to
directly enter the spinal cord due to the nature and size
of the molecules (protein/peptide).9
Recent studies have suggested that the use of replica-
tion-defective adenoviral vectors has provided a novel
strategy for direct gene transfer into the central nervous
system.10 Further, an adenoviral vector can transduce a
given gene into nonproliferating cells such as neuronal
cells.11 We12 previously have demonstrated that the
transfer and expression of the lacZ gene in motor neu-
ron cells suggests the onset of apoptosis. Furthermore,
we8 have demonstrated that GDNF gene delivery
reduces ischemic brain injury with a reduction of
TUNEL staining and the immunohistochemistry for
caspases. However, a possible protective effect of
GDNF on spinal cord ischemia and the exact mecha-
nism of the ameliorative effect of GDNF on ischemic
spinal cord injuries are not fully understood. Therefore,
we investigated the possible protective effect of adeno-
virus-mediated GDNF gene delivery on transient spinal
cord ischemia in rabbits.
Materials and methods 
Animal models. Forty-one domesticated white rabbits
from Japan (Funakoshi, Japan), weighing 2 to 3 kg, were
used in this study and were divided into 3 groups: those with
sham operation 2 days after the vehicle was injected into the
spinal cord (sham control, n = 3), those with 15 minutes of
spinal cord ischemia 2 days after the lacZ gene was injected
into the spinal cord (lacZ-treated group, n = 19), and those
with a 15-minute ischemic insult 2 days after the GDNF gene
was injected into the spinal cord (GDNF-treated group, n =
19). Anesthesia was induced with intramuscular administra-
tion of ketamine at a dose of 50 mg/kg and maintained with
2% halothane inhalation. A 5F thermodilution catheter (405;
B. Braun Melsungen AG, Melsungen, Germany) was insert-
ed through the femoral artery and advanced from the inguinal
band 15 cm forward into the abdominal aorta. Preliminary
investigation confirmed that the balloon on the distal end of
the thermodilution catheter was positioned 0.5 to 1.5 cm just
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distal to the left renal artery. During the experiment, the aor-
tic pressure was continuously monitored from both the prox-
imal and distal positions of the distal balloon. The body tem-
perature was monitored with a rectal thermistor and
maintained at 37°C with the aid of a heating pad during the
operation and subsequent ischemia. The animals were then
allowed free access to water and food at the ambient temper-
ature. They were put to death with deep anesthesia by means
of sodium pentobarbital (100 mg/kg intravenously) at 8 hours
(n = 3), 1 day (n = 3), 2 days (n = 5), and 7 days (n = 5) after
reperfusion. In the sham control group and in the 0-hour
group, the animals were put to death after insertion of the
catheter into the abdominal aorta without inflating the bal-
loon. The tissue samples for immunohistochemistry were
frozen in powdered dry ice and stored at –80°C. The samples
for histologic examination were fixed by immersing them in
4% paraformaldehyde in a 0.1 mol/L concentration of phos-
phate buffer and then stored at 4°C for 1 week. They were
then cut transversely at about the L2 or L3 level and finally
embedded in paraffin. In the experiment, the rabbits were
treated in accordance with the Declaration of Helsinki and
the “Guiding Principles in the Care and Use of Animals.”
Also, the experimental and animal care protocol was
approved by the Animal Care Committee of the Tohoku
University School of Medicine.
Neurologic assessment. Neurologic function was
observed at 2 and 7 days after the procedure, and animals
were classified into a 5-point scale according to the method
of Johnson, Kraimer, and Graeber13: 0 = hind-limb paralysis;
1 = severe paraparesis; 2 = functional movement, no hop; 3 =
ataxia, disconjugate hop; 4 = minimal ataxia; 5 = normal
function. Two individuals, without knowledge of the treat-
ment, independently graded the neurologic function.
Statistical analyses of the neurologic scores were performed
with the Mann-Whitney U test.
Adenoviral vector constructs. The recombinant adenovi-
ral vector used in this study was based on the type 5 ade-
novirus, which was essentially the same as that in previous
reports.14,15 In brief, the E3 region of the adenovirus genome
was deleted, and a cassette containing the complementary
DNA for rat GDNF or the Escherichia coli lacZ gene (used
as a control vector) driven by a cytomegalovirus promoter
and simian virus 40 polyadenylation signal was inserted into
the E1 region of the adenovirus genome by homologous
recombination. With this promoter, the rat GDNF or E coli
lacZ gene of the episomally located adenovirus vectors could
be transcribed as messenger RNA in the nucleus, and then the
mRNA could be translated into the protein in cytoplasm. The
adenoviral vector, designated as Ad-GDNF or Ad-lacZ, was
propagated in 293 cells (CRL1573; American Type
Collection) and purified and titered as previously
described.14,15
In vivo gene transfer. Two days before spinal cord
ischemia, the adenoviral vector was inoculated. With immo-
bilization using a stereotactic apparatus, either Ad-GDNF or
Ad-lacZ (2.5 × 109 plaque-forming units in a 5-µL vector
vehicle consisting of 10 mmol/L Tris-HCl, pH 7.4, 1 mmol/L
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MgCl2, and 10% glycerol) was administered into the dorsal
white matter via the L3 intervertebral disk to a depth of 20
mm from the skin surface. A 10-µL sterile Hamilton syringe
(the Gasthghit High-performance Syringe, Hamilton, Reno,
Nev) and a 26-gauge needle (0.47-mm outer diameter) were
used. In the sham control group, 3 animals that were injected
with vehicle (5 µL of vehicle consisting of 10 mmol/L Tris-
HCl, pH 7.4, 1 mmol/L MgCl2, and 10% glycerol) were
allowed to recover immediately after the sham operation.
Preliminary investigation confirmed that the end of the nee-
dle was positioned 1 to 3 mm just dorsal to the central canal
of the spinal cord. The injection (5 µL) was slowly complet-
ed over 10 minutes. During the injection, the needle was
withdrawn gradually at a rate of 3.5 mm in 10 minutes and
was finally removed after 10 minutes.
Histologic study. The sections were stained with hema-
toxylin-eosin and examined by light microscopy. An
observer, unaware of the animal group and neurologic out-
come, examined each slide. With hematoxylin-eosin stain-
ing, the cells were considered “dead” if the cytoplasm was
diffusely eosinophilic and “viable” if the cells demonstrat-
ed basophilic stippling (that is, if they contained Nissl sub-
stance). The spinal cords were removed, fixed by immer-
sion in 4% paraformaldehyde in 0.1 mol/L phosphate
buffer for 7 days, and then embedded in paraffin. The num-
ber of intact large motor neuron cells in the Rexed laminae
VII, VIII, and IX was counted. Statistical analyses of the
number of motor neurons were performed with the Mann-
Whitney U test.
TUNEL staining. To detect DNA fragmentation in the nuclei
of the cells, we applied a modified TUNEL reaction to the
cryosections according to our previously reported method16
using a kit (4810-30-K; Trevigen, Inc, Gaithersburg, Md). After
deparaffinizing, the nuclei of the tissue sections were stripped
of proteins by incubation with 20 µg/mL proteinase K for 10
minutes. After being treated with 0.3% hydrogen peroxide
(H2O2) in distilled water for 5 minutes, they were incubated
with TdT and biotinylated dUTP in a TdT buffer in a humidi-
fied chamber at 37°C for 120 minutes. Further incubation with
peroxidase-conjugated streptavidin was carried out for 30 min-
utes at room temperature. The slices were colored with
diaminobenzadine (DAB)/H2O2 solution and then counter-
stained with methyl green. To determine the number of motor
neurons that underwent apoptosis, we counted the motor neu-
rons that were positive or negative in the TUNEL staining.
Statistical analyses of the number of TUNEL-positive motor
neurons were performed with the Mann-Whitney U test.
GDNF and caspase-3 immunocytochemistry. We also per-
formed an immunohistochemical study to investigate the
change in the expression of GDNF and caspase-3. The frozen
sections, 10 µm in thickness, were fixed in acetone, rinsed in a
0.1 mol/L concentration of phosphate-buffered saline solution
for 20 minutes, and blocked in 2% normal horse serum for 2
hours at room temperature. They were then incubated with pri-
mary antibodies in 10% normal horse serum or 10% normal
rabbit serum and 0.3% Triton-X 100 octylphenoxypoly-
ethoxyethanol (Union Carbide Corporation, Danbury, Conn)
for 20 hours at 4°C. The primary antibodies used were as fol-
lows: mouse monoclonal antibody against GDNF (MAB212;
R & D Systems, Inc, Minneapolis, Minn) and goat polyclonal
antibody against caspase-3 (SC 1217; Santa Cruz Bio-
technology, Inc, Santa Cruz, Calif), and each dilution was as
follows: antibody against GDNF of 1:200 and that against cas-
pase-3 of 1:200.
After endogenous peroxidase activity had been quenched
by exposing the slides to 0.3% H2O2 and 10% methanol for
20 minutes, the slides were washed in phosphate-buffered
saline solution. They were then incubated for 3 hours with
biotinylated anti-mouse immunoglobulin G (PK-6102;
Vector Laboratories, Burlingame, Calif) and biotinylated
anti-goat immunoglobulin G (PK-6105; Vector Labora-
tories) in a 1:200 dilution of phosphate-buffered saline
solution containing 0.018% normal horse or rabbit serum,
respectively. Subsequently, they were incubated with
avidin-biotin-horseradish peroxidase complex (PK-6102;
Vector Laboratories). The slices were colored with a
DAB/H2O2 solution, and the cytoplasms were counter-
stained with hematoxylin. So that the specific binding of
the antibody to the protein could be ascertained, a set of
sections were stained in a similar way without the primary
antibody. The staining was categorized into 4 grades in the
following manner: no stain (–), slightly stained (±), moder-
ately stained (+) or densely stained (2+).
Results
Neurologic outcome. The results are summarized in
Table I. There were no neurologic changes in the sham
Table I.  Neurologic score at 2 and 7 days after 15 minutes of ischemia in animal groups treated with lacZ or
GDNF before ischemia
LacZ GDNF
Animal Sham 2 d 7 d 2 d 7 d
1 5 5 2 5 5
2 5 5 3 5 3
3 5 4 2 5 4
4 5 4 3 4 4
5 5 3 2 4 3
Mean ± SD 5 ± 0 4.2 ± 0.83 2.4 ± 0.55* 4.5 ± 0.55 3.8 ± 0.84
*P = .021 compared with 7 days after procedure, lacZ- and GDNF-treated group.
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control group or at 0 hours, 8 hours, and 1 day of the
lacZ- and GDNF-treated groups. In the lacZ-treated
group at 2 days after the procedure (n = 5), 2 rabbits
(40%) were normal (grade 5), 2 (40%) had minimal
ataxia (grade 4), and 1 (20%) had ataxia (grade 3). In
the lacZ-treated group at 7 days after the procedure (n
= 5), 3 rabbits (60%) did not hop (grade 2) and 2 (40%)
had ataxia (grade 3). 
In the GDNF-treated group at 2 days after the proce-
dure (n = 5), 3 rabbits (60%) were normal (grade 5) and
2 (40%) had minimal ataxia (grade 4). In the GDNF-
treated group at 7 days after the procedure (n = 5), 1
rabbit (20%) was normal (grade 5), 2 (40%) had mini-
mal ataxia (grade 4), and 2 (40%) had ataxia (grade 3).
There was a significant difference in the Johnson neu-
rologic scores at 7 days after the procedure between the
GDNF-treated group and the lacZ-treated group (3.8 ±
0.84 vs 2.4 ± 0.55; P = .021). Fifteen minutes of
ischemia 2 days after the GDNF pretreatment with the
adenoviral vector did not affect the neuronal function. 
Histologic study. The results of the cell count in
Rexed laminae VII, VIII, and IX in the paraffin sections
obtained from this study in animals are shown in Figs
1 and 2. Following the sham control group, no signifi-
cant change was seen in the motor neurons (21.2 ± 3.0)
(Fig 2). There were no histologic changes at 0 hours, 8
hours, and 1 and 2 days of the lacZ- and GDNF-treat-
ed groups. After the 15 minutes of ischemia in the lacZ
treatment group on the seventh day of reperfusion,
about 70% of the motor neuron cells in the ventral gray
matter were lost (Fig 1, A, and Fig 2). The damage to
the motor neuron cells after the GDNF treatment was
only slight, and large populations of cells were pre-
served (Fig 1, B, arrowheads, and Fig 2). Small motor
neurons and intermediate neurons survived the
ischemia. The dorsal horn neurons were intact after 15
minutes of ischemia (data not shown). A significant
recovery in the number of motor neuron cells was
found in GDNF-treated group as compared with the
lacZ-treated group 7 days after the procedure (16.2 ±
4.8 vs 7.8 ± 2.6; P = .0361) (Fig 2).
TUNEL staining. Photographs of TUNEL staining
of the spinal cords are shown in Fig 3. There were no
TUNEL reactions in motor neurons in the sham control
group and at 0 hours, 8 hours, and 1 day in the lacZ-
and GDNF-treated groups (data not shown). Two days
after the ischemic insult, about 50% of the positive
Fig 1.  Representative photographs of spinal cord sections
stained with hematoxylin-eosin at 7 days after reperfusion.
After being subjected to 15 minutes of ischemia 2 days before
the lacZ treatment, about 70% of the motor neuron cells in the
ventral gray matter were lost at 7 days of reperfusion (A). After
being subjected to 15 minutes of ischemia 2 days before the
GDNF treatment, almost all of the motor neuron cells were pre-
served at 7 days of reperfusion (B, arrowheads). Bar = 100 µm.
Fig 2. Number of intact motor neurons in the sham control
group and in the lacZ- and GDNF-treated groups at 7 days
after reperfusion.
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staining in the motor neuron cells in the ventral gray
matter were detected to have brown with granular pat-
tern (Fig 3, A), indicating the cells that were undergo-
ing double-strand DNA breaks mainly associated with
apoptosis in lacZ-treated group. The neurons in the
dorsal horn of the gray matter and white matter were
not positive for TUNEL staining (data not shown). 
In the GDNF-treated group at 2 days after the proce-
dure, a few of the motor neurons were positive for
TUNEL staining (Fig 3, B). For quantitative measure-
ment, the number of motor neurons that were positive
or negative in TUNEL was recorded in each specimen
in a blind fashion (Fig 4). There was a significant dif-
ference in the number of TUNEL-positive motor neu-
rons at 2 days after the procedure between the GDNF-
treated and lacZ-treated groups (2.2 ± 1.3 vs 9.2 ± 1.5;
P = .0086).
Immunohistochemical study. The immunoreactive
GDNF and caspase-3 sections from the spinal cords are
shown in Figs 5 and 6. The spinal cords of sham con-
trol and lacZ-treated animals at 0 hour did not show
GDNF (Fig 5, D, Table II) and caspase-3 (Fig 6, D,
Table II) antigen immunoreactivity in any of the cells.
In the lacZ-treated group, the motor neurons selective-
ly showed strong immunoreactivity for GDNF (Fig 5,
E, Table II) and caspase-3 (Fig 6, E, Table II) antigen
by 8 hours of reperfusion after 15 minutes of ischemia.
Immunoreactivity of the motor neuron cells for GDNF
(Fig 5, F, Table II) and caspase-3 (Fig 6, F, Table II)
antigen were almost lost in the motor neurons by 1, 2,
and 7 days. However, the spinal cords of the GDNF-
treated animals at 0 hour already showed GDNF in the
motor neuron cells (Fig 5, A, Table II) and selectively
showed a strong immunoreactivity for GDNF by 8
hours of reperfusion (Fig 5, B, Table II), and the induc-
tion was sustained until 7 days of reperfusion (Fig 5, C,
Table II). On the other hand, in the spinal cords of the
GDNF-treated group, a few motor neurons showed cas-
pase-3 (Fig 6, B, Table II) antigen immunoreactivity. 
Discussion
We12,16 previously demonstrated delayed and selec-
tive motor neuron death in the lumbar region of the rab-
Fig 3.  TUNEL staining in the ventral gray matter of the lacZ-
treated spinal cord (A) and GDNF-treated spinal cord (B)
after 2 days of reperfusion following 15 minutes of ischemia.
Arrowheads show the motor neuron cell nuclei that have pos-
itive TUNEL staining. Bar = 100 µm.
Fig 4. Number of TUNEL-positive motor neurons in the
lacZ- and GDNF-treated groups at 2 days after reperfusion. 
Some trophic factors are known to be up-regulated in
the peripheral nerves after axotomy in adult mam-
mals.20 The survival of adult motor neurons after axo-
tomy and their death after avulsion may reflect the
availability of local sources of GDNF in the axo-
tomized peripheral nerves.21 Several clinical trials test-
ing systemic GDNF treatment have mixed results, with
some showing reduction in the disease progression,22,23
while others demonstrated little or no efficacy.24 In
some cases serious adverse side effects were also
reported.25 The poor effectiveness of systemic GDNF
treatment may be caused by the short serum half-life,
targeting of inappropriate sites, and the blood-brain
barrier. 
In recent years, the use of replication-defective ade-
noviral vectors has provided a novel strategy for direct
gene transfer into the brain.10,11 Initial experimental
models of gene transfer into the brain were performed
with replication-defective or latency-prone neurotroph-
ic viruses such as the herpes simplex virus type.26
Although herpes virus vectors can carry a relatively
large gene up to 36 kb, cytopathogenicity such as neu-
ronal death may be a major disadvantage.27 Retroviral
vectors also have the potential of delivering genes into
the neurons.28 However, retroviral vectors do not infect
nondividing cells such as neurons, and in vivo risks
such as mutagenesis and tumorigenesis are also indi-
cated.27 Direct injection of plasmid vector with or with-
out conjugation of liposome also carries genes to the
brain.29 However, efficacy of gene expression is low.27
The advantageous feature of adenoviral vectors is
that they are capable of infecting a variety of terminal-
ly differentiated cell types such as neurons and mus-
cles.27 It is generally considered that the ischemic
spinal cord usually has a translational problem of gene
expression and cannot effectively produce protein even
if the mRNA is present.9 Our present results show that
the motor neurons in the ventral horn can effectively
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bit spinal cord with the same reproducible model.
Fifteen minutes of ischemia is a relatively short
ischemic period in comparison with those of previous-
ly reported models,13 and after the ischemia, delayed
and selective motor neuron damage was observed only
after 7 days of reperfusion in this model.12,16 This phe-
nomenon is known as selective neuronal death in motor
neuron cells after spinal cord ischemia.12,16
Many recent studies on ischemic cerebrovascular
disease have revealed two major ways for neuronal
cell death to occur: necrosis and apoptosis.9 Necrosis
usually occurs after acute ischemia, due to a reduction
in the tissue ATP level accompanied by edema forma-
tion and concomitant death of glial and vascular cells.
In contrast, neuronal apoptosis occurs days after
ischemia without a reduction in the ATP level, nor
with edema formation and concomitant death of glial
and vascular cells. Our previous study reported that
the induction of CPP32 (caspase-3) antigen in
ischemic spinal motor neurons was related to the
apoptosis of cells, which eventually die.17 In any
event, some putative protective proteins such as neu-
rotrophic factors and heat shock protein may prevent
this neuronal death if the proteins can effectively
work under emergency conditions such as
ischemia.9,16 We previously demonstrated selective
induction of GDNF and RET (REarranged during
Transfection) in motor neurons at 8 hours of reperfu-
sion after 15 minutes of ischemia in rabbits.18 These
results may be related to the transient functional
recovery of neurons after ischemia. However, the
immunoreactivity of motor neuron cells for GDNF
and RET returned to the sham control level by day 1
and almost all of the motor neurons eventually died. 
In the present study, we demonstrated that about 70%
of motor neurons in the spinal cord were selectively
lost by 7 days after transient ischemia, and that was in
accordance with our previous report.12,16 On the other
hand, the TUNEL study revealed that about 50% of
motor neurons had breaks in the genomic DNA at 2
days (Fig 3). It is known that nuclei of neurons under-
going apoptosis show positivity with TUNEL staining
and have granular pattern; however, those with necrosis
show slight staining with a homogeneous pattern.19
Because the nuclei at 2 days after ischemia in this study
were densely stained in a granular pattern (Fig 2, B),
the motor neurons were suggested to be undergoing
apoptosis. In addition, the neuronal cells showed some
morphologic features of apoptosis with hematoxylin-
eosin staining (Fig 1, C). Through induction of cas-
pase-3, as will be described in detail later, we could at
least infer the involvement of apoptotic machinery in
the motor neuron death in this model.
Table II.  Summary of the GDNF and caspase-3
expression in lacZ- or GDNF-treated spinal cords
LacZ-treated GDNF-treated
GDNF Caspase-3 GDNF Caspase-3
0 h ––– ––– +++ –––
8 h +++ 2+2+2+ 2+2+2+ ±±±
1 d ––– ––– 2+2+2+ –––
2 d ––– ––– 2+2+2+ –––
––– ––– 2+2+ –––
7 d ––– ––– 2+2+2+ –––
––– ––– ++ –––
The staining was categorized as follows: no staining (—); slight (±); moder-
ate (+); dense (2+). N = 3 at sham, 8 hours, and 1 day aftter reperfusion; n =
5 at 2 and 7 days after reperfusion.
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Fig 5.  Immunostaining against GDNF in the motor neurons of the GDNF- or lacZ-treated groups in a sham-operated
spinal cord (A and D), at 8 hours (B and E), 1 day (F, lacZ-treated group), and 7 days (C, GDNF-treated group) of
reperfusion following 15 minutes of ischemia. Arrowheads show motor neurons expressing immunoreactive GDNF.
Bar = 100 µm.
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Fig 6.  Immunostaining against caspase-3 in motor neurons in the GDNF- or lacZ-treated groups in a sham-oper-
ated spinal cord (A and D), at 8 hours (B and E), and 1 day (C and F) of reperfusion following 15 minutes of
ischemia. Arrowheads show a motor neuron expressing immunoreactive caspase-3. Bar = 100 µm.
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like immunoreactivities in rabbit spinal cord after transient
ischemia. Neurosci Lett 1999;276:123-6.
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1156 Sakurai et al The Journal of Thoracic and
Cardiovascular Surgery
December 2000
express the GDNF gene as a functional protein in
ischemic spinal cord. This may be because the GDNF
gene is relatively small (<700 bp) and the adenoviral
vector locates in the episomal position but is not incor-
porated in the genome-like retroviral vectors. This may
also be due to a mild reduction in protein synthesis in
the case of ischemia, and no or only a minimal protein
expression may be well correlated to the complete inhi-
bition of protein synthesis associated with calcium
overload after reperfusion. We16 previously demon-
strated that the motor neurons of the ventral horn could
effectively express the lacZ gene as a functional protein
in ischemic spinal cord.
Caspase-3 (CPP32) is a member of the interleukin 1
converting enzyme–like proteases, which are related to
mammalian apoptosis and inflammation.30 Our previ-
ous study showed that an increase in the immunoreac-
tivity of apoptosis-inducing protein, caspase-3, was
demonstrated in the motor neuron cells of the spinal
cord after 15 minutes of transient ischemia, and the
peak immunostaining intensity of caspase-3 after the
ischemic insult preceded the DNA fragmentation in the
spinal cord.17 This finding suggests that overexpression
of caspase-3 may play an important role in the induc-
tion of DNA fragmentation in the spinal cord. The
expression of caspase-3 precedes the appearance of
neuronal damage and may therefore be implicated in
the activation of apoptosis.17 In this study, the GDNF-
treated group showed a reduction in the number of
TUNEL- and caspase-3–positive motor neuron cells.
These results suggest that GDNF may play a protective
role against spinal cord ischemia in rabbits and that the
reduction of motor neuron death by GDNF is greatly
associated with a reduction in DNA fragmentation and
apoptotic signals of the caspase-3 cascade.
Furthermore, our study is the first report that demon-
strated gene therapy for spinal cord ischemia. 
In summary, we demonstrated the transfer and
expression of GDNF in motor neuron cells and the pro-
tective effect of GDNF on spinal cord ischemia with a
reduction in the apoptotic process. Therefore, GDNF
could become a strong candidate for a use as a thera-
peutic agent in the treatment of ischemic spinal cord
injury in the near future. 
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